Northpond Ventures

Longitude Capital

Menlo Ventures

Opna Bio

Are you attending the AACR-NCI-EORTC International Conference in Boston next week? We’re looking forward to presenting preclinical data on Opna’s EP300/CBP bromodomain inhibitors, OPN-6602 and OPN-6742, in metastatic castration-resistant prostate cancer (mCRPC). 
Details: Sat, Oct 14th, Hynes Convention Center, Abstract #CO85, Poster Session C, Level 2, Exhibit Hall D, 12:30-4 pm ET #AACR-NCI-EORTC #prostatecancer #BETinhibition

Check out Opna’s emerging company profile in this week’s BioCentury, which details the company’s formation based on a novel discovery from Dr. Doug Hanahan’s lab at the Swiss Federal Institute of Lausanne revealing the fragile X mental retardation protein (FMRP) as a new cancer target. Armed additionally with five programs licensed from the former Plexxikon, including two clinical-stage compounds, Opna is advancing its robust pipeline in multiple cancer indications, including myelofibrosis and histiocytosis. https://lnkd.in/g6D9ye8Z (subscription req'd) #FMRP #oncology #Phase2

We are thrilled to announce our official debut as Opna Bio this morning, launching with a $38 million Series A financing from Longitude Capital, Northpond Ventures and Menlo Ventures. Opna is a rare kind of start-up, founded to advance a novel oncology discovery target (fragile X mental retardation protein, or FRMP) that plays a key role in helping tumors evade immune destruction, and strengthened with a portfolio of validated clinical and preclinical compounds acquired from Plexxikon, Inc. The company was cofounded by Gideon Bollag, PhD, CEO, Douglas Hanahan, PhD, and Joseph Schlessinger, PhD, who collectively have garnered multiple FDA-approved oncology drugs to their names.
https://lnkd.in/gGEydBWV

More about FMRP’s role in tumor immune evasion can be viewed in last week’s Science. https://lnkd.in/gWx_en5d
#FMRP #oncologypioneers #SeriesA #overcomingtumorimmunosuppression #addressinghallmarksofcancer

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	de4b8c06
crunchbase profile	general
li profile	general	Oct 27, 2023 11:49 AM	9498a5ae
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:OPNABIO

Opna Bio